Effect of steatosis and inflammation on liver fibrosis in chronic hepatitis C

Liver International

Volumn 29, Issue 2, 2009, Pages 153-158

  Nieminen, Urpo ^a   Arkkila, Perttu E T ^a   Kärkkäinen, Päivi ^a   Färkkilä, Martti A ^a  

^a HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

Author keywords

Activity; Fibrosis; Genotype; Hepatitis C virus; Liver biopsy; METAVIR; Risk factors; Steatosis; Viral hepatitis

Indexed keywords

AGE; ARTICLE; BODY MASS; CLINICAL ASSESSMENT; CONTROLLED STUDY; CORRELATION FUNCTION; DISEASE ACTIVITY; DISEASE DURATION; DISEASE SEVERITY; FEMALE; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; INFLAMMATION; LIVER BIOPSY; LIVER FIBROSIS; MAJOR CLINICAL STUDY; MALE; RISK FACTOR; SCORING SYSTEM; STEATOSIS;

ADOLESCENT; ADULT; AGE FACTORS; AGED; BIOPSY; BODY MASS INDEX; FATTY LIVER; FEMALE; FINLAND; GENOTYPE; HEPACIVIRUS; HEPATITIS C; HUMANS; INFLAMMATION; LIVER CIRRHOSIS; LOGISTIC MODELS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; RISK FACTORS;

EID: 58149518683     PISSN: 14783223     EISSN: 14783231     Source Type: Journal    
DOI: 10.1111/j.1478-3231.2008.01779.x     Document Type: Article

References (25)

1. Poynard T, Bedossa P, Opolon P. Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups. Lancet 1997; 349: 825-32.
2. Ryder SD, Irving WL, Jones DA, Neal KR, Underwood JC, Trent Hepatitis C Study Group. Progression of hepatic fibrosis in patients with hepatitis C: A prospective repeat liver biopsy study. Gut 2004; 53: 451-5.
3. Sebastiani G, Alberti A. Non invasive fibrosis biomarkers reduce but not substitute the need for liver biopsy. World J Gastroenterol 2006; 12: 3682-94. Review.
4. Rockey DC, Bissell DM. Noninvasive measures of liver fibrosis. Hepatology 2006; 43(Suppl. 1): S113-20.
5. Kleiner DE. The liver biopsy in chronic hepatitis C: A view from the other side of the microscope. Semin Liver Dis 2005; 25: 52-64.
6. Perrillo RP. The role of liver biopsy in hepatitis C. Hepatology 1997; 26(Suppl. 1): 57S-61S.
7. Poynard T, McHutchison J, Davis GL, et al. Impact of interferon alfa-2b and ribavirin on progression of liver fibrosis in patients with chronic hepatitis C. Hepatology 2000; 32: 1131-7.
8. Dienstag JL, McHutchison JG. American Gastroenterological Association medical position statement on the management of hepatitis C. Gastroenterology 2006; 130: 225-30.
9. Booth JC, O'Grady J, Neuberger J, The Royal College of Physicians of London and the British Society of Gastroenterology. Clinical guidelines on the management of hepatitis C. Gut 2001; 49(Suppl. 1): 1-21.
10. Bedossa P, Poynard T. An algorithm for the grading of activity in chronic hepatitis C. The METAVIR cooperative study group. Hepatology 1996; 24: 289-93.
11. Kleiner DE, Brunt EM, Nonalcoholic Steatohepatitis Clinical Research Network, et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 2005; 41: 1313-21.
12. Seeff LB. Natural history of chronic hepatitis C. Hepatology 2002; 36(Suppl. 1): S35-46.
13. Tong MJ, El-Farra NS, Reikes AR, Ruth LC. Clinical outcomes after transfusion-associated hepatitis C. N Engl J Med 1995; 332: 1463-6.
14. Collier JD, Woodall T, Wight DG, Shore S, Gimson AE, Alexander GJ. Predicting progressive hepatic fibrosis stage on subsequent liver biopsy in chronic hepatitis C virus infection. J Viral Hepat 2005; 12: 74-80.
15. Rubbia-Brandt L, Fabris P, Paganin S, et al. Steatosis affects chronic hepatitis C progression in a genotype specific way. Gut 2004; 53: 406-12.
16. Grassi A, Ballardini G, Susca M, et al. HCV liver infection and liver steatosis: Evidence for indirect mechanisms in genotype 3? Aliment Pharmacol Ther 2005; 22(Suppl. 2): 79-82.
17. Negro F. Mechanisms and significance of liver steatosis in hepatitis C virus infection. World J Gastroenterol 2006; 12: 6756-65.
18. Asselah T, Rubbia-Brandt L, Marcellin P, Negro F. Steatosis in chronic hepatitis C: Why does it really matter? Gut 2006; 55: 123-30.
19. Hübscher SG. Histological assessment of non-alcoholic fatty liver disease. Histopathology 2006; 49: 450-65.
20. Adinolfi LE, Gambardella M, Andreana A, Tripodi MF, Utili R, Ruggiero G. Steatosis accelerates the progression of liver damage of chronic hepatitis C patients and correlates with specific HCV genotype and visceral obesity. Hepatology 2001; 33: 1358-64.
21. Asselah T, Boyer N, Guimont MC, et al. Liver fibrosis is not associated with steatosis but with necroinflammation in French patients with chronic hepatitis C. Gut 2003; 52: 1638-43.
22. Serfaty L, Andreani T, Giral P, Carbonell N, Chazouilleres O, Poupon R. Hepatitis C virus induced hypobetalipoproteinemia: A possible mechanism for steatosis in chronic hepatitis C. J Hepatol 2001; 34: 428-34.
23. Perlemuter G, Sabile A, Letteron P, et al. Hepatitis C virus core protein inhibits microsomal triglyceride transfer protein activity and very low density lipoprotein secretion: A model of viral-related steatosis. FASEB J 2002; 16: 185-94.
24. Mirandola S, Realdon S, Iqbal J, et al. Liver microsomal triglyceride transfer protein is involved in hepatitis C liver steatosis. Gastroenterology 2006; 130: 1661-9.
25. Poynard T, Ratziu V, Charlotte F, Goodman Z, McHutchison J, Albrecht J. Rates and risk factors of liver fibrosis progression in patients with chronic hepatitis C. J Hepatol 2001; 34: 730-9.